Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Metitepine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 5/20 | 0.82 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.82 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.82 |
| ▸ | MTOR known ✓ | P42345 | 2/20 | 0.82 |
| ▸ | DRD2 known ✓ | P14416 | 10/20 | 0.61 |
| ▸ | HRH1 known ✓ | P35367 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | TP53 | P04637 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | HTR7 | P34969 | 4/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.82 |
| ▸ | NPC1 | O15118 | 2/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metitepine SCHEMBL15475310 | 1.00 | MAPT (1.00) | MAPTTP53CYP3A4MEN1LMNA | |
| Metitepine SCHEMBL113526 | 0.91 | HTR7 (1.00) | MAPTTP53CYP3A4MEN1LMNA | |
| Metitepine SCHEMBL14359602 | 0.91 | HTR7 (1.00) | MAPTTP53CYP3A4MEN1LMNA | |
| Metitepine SCHEMBL7517783 | 0.91 | HTR7 (1.00) | MAPTTP53CYP3A4MEN1LMNA | |
| Metitepine SCHEMBL29496251 | 0.91 | HTR7 (1.00) | MAPTTP53CYP3A4MEN1LMNA | |
| Maleic Acid SCHEMBL11878955 | 0.89 | MAPT (0.80) | MAPTTP53CYP3A4MEN1LMNA | |
| Fumaric Acid SCHEMBL11878965 | 0.89 | MAPT (0.80) | MAPTTP53CYP3A4MEN1LMNA | |
| Metitepine SCHEMBL31360614 | 0.88 | MAPT (1.00) | MAPTTP53CYP3A4MEN1LMNA | |
| Metitepine SCHEMBL466985 | 0.88 | MAPT (1.00) | MAPTTP53CYP3A4MEN1LMNA | |
| Fumaric Acid SCHEMBL11876998 | 0.87 | MAPT (0.76) | MAPTTP53CYP3A4MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3752137-A1 | REPURPOSING COMPOUNDS FOR THE TREATMENT OF INFECTIONS AND FOR MODULATING THE COMPOSITION OF THE GUT MICROBIOME | European Molecular Biology Laboratory (DE) | 2020-12-23 | — | — | EP | claimed |
| US-20200368218-A1 | REPURPOSING COMPOUNDS FOR THE TREATMENT OF INFECTIONS AND FOR MODULATING THE COMPOSITION OF THE GUT MICROBIOME | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2020-11-26 | — | — | US | claimed |
| WO-2019158559-A1 | REPURPOSING COMPOUNDS FOR THE TREATMENT OF INFECTIONS AND FOR MODULATING THE COMPOSITION OF THE GUT MICROBIOME | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2019-08-22 | — | — | WO | claimed |
| EP-3524237-A1 | REPURPOSING COMPOUNDS FOR THE TREATMENT OF INFECTIONS AND FOR MODULATING THE COMPOSITION OF THE GUT MICROBIOME | European Molecular Biology Laboratory (DE) | 2019-08-14 | — | — | EP | claimed |
| US-20140350081-A1 | INSECT G-COUPLED RECEPTORS USEFUL AS TARGETS FOR INSECTICIDES AND COMPOUNDS AND REAGENTS IDENTIFIED USING THE SAME | US ARMY, SECRETARY OF THE ARMY | 2014-11-27 | — | — | US | claimed |
| WO-2013067519-A2 | INSECT AND TICK G-COUPLED RECEPTORS USEFUL AS TARGETS FOR INSECTICIDES AND COMPOUNDS AND REAGENTS IDENTIFIED USING THE SAME | PURDUE RESEARCH FOUNDATION (US) | 2013-05-10 | — | — | WO | claimed |
| US-20110224141-A1 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2011-09-15 | — | — | US | claimed |
| WO-2009148623-A2 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2009-12-10 | — | — | WO | claimed |
| WO-2004028548-A2 | INHIBITORS OF THE NITRIX OXIDE SYNTHASE III (NOS III) AS NEUROPROTECTIVE AGENTS | CARBOMER, INC. (US) | 2004-04-08 | — | — | WO | claimed |
| US-20040063612-A1 | Neuroprotective agents | CARBOMER, INC. | 2004-04-01 | — | — | US | claimed |
| US-20250161375-A1 | METHODS OF DECREASING DYSBIOSIS AND RESTORING A MICROBIOME | VEDANTA BIOSCIENCES, INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-12161680-B2 | Methods of decreasing dysbiosis and restoring a microbiome | VEDANTA BIOSCIENCES, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240148723-A1 | MYCOBACTERIUM TUBERCULOSIS COMPOSITIONS AND METHODS | PZA INNOVATION LLC | 2024-05-09 | — | — | US | disclosed |
| US-20240115564-A1 | HTR1F ANTAGONISTS FOR IMPROVEMENT OF BETA CELL SURVIVAL AND FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230330157-A1 | MODULATION OF MICROBIOTA FUNCTION BY GENE THERAPY OF THE MICROBIOME TO PREVENT, TREAT OR CURE MICROBIOME-ASSOCIATED DISEASES OR DISORDERS | ELIGO BIOSCIENCE (FR) | 2023-10-19 | — | — | US | disclosed |
| US-20040063612-A1 | Neuroprotective agents | CARBOMER, INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2004019921-A2 | USE OF APOPTOSIS INDUCING AGENTS IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF LIVER DISEASES | UNIVERSITY OF SOUTHAMPTON (GB) | 2004-03-11 | — | — | WO | disclosed |
| US-20030032580-A1 | Use of agonists or antagonists of the 5-HT7 receptor to treat disorders of the bladder | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-02-13 | — | — | US | disclosed |
| US-6440988-B1 | Use of agonists or antagonists of the 5-HT7 receptor to treat disorders of the bladder | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-08-27 | — | — | US | disclosed |
| WO-2000069437-A1 | USE OF AGONISTS OR ANTAGONISTS OF THE 5-HT7 RECEPTOR TO TREAT DISORDERS OF THE BLADDER | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350081-A1 | INSECT G-COUPLED RECEPTORS USEFUL AS TARGETS FOR INSECTICIDES AND COMPOUNDS AND REAGENTS IDENTIFIED USING THE SAME | DDT, ADRA2C, MCHR1 | HTR2C 29/4885HTR1A 48/4885HTR2A 56/4885 |
| US-20240115564-A1 | HTR1F ANTAGONISTS FOR IMPROVEMENT OF BETA CELL SURVIVAL AND FUNCTION | HTR1F, HTR1D, HTR1E | HTR2C 17/4885HTR1A 4/4885HTR2A 13/4885 |
| US-20040063612-A1 | Neuroprotective agents | GAP43, NLN, NOS3 | HTR2C 2479/4885HTR1A 1057/4885HTR2A 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.